Increasing cord atrophy in early relapsing-remitting multiple sclerosis: A 3 year study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 1, 2006, Pages 51-55

  Rashid, W ^a   Davies, G R ^a   Chard, D T ^a   Griffin, C M ^a   Altmann, D R ^b   Gordon, R ^a   Thompson, A J ^a   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; SAMPLE SIZE; SCORING SYSTEM; SPINAL CORD ATROPHY; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

EID: 29644435309     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.068338     Document Type: Article

References (41)

1. Lin X, Tench CR, Evangelou N, et al. Measurement of spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004;14:20S-26S.
2. Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 1978;4:151-62.
3. Lassmann H. Pathology of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, et al. McAlpine's multiple sclerosis, 3rd ed. London: Churchill Livingstone, 1998:323-57.
4. Bot JCJ, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62:226-33.
5. Bergers E, Bot JC, De Groot G, et al. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 2002;59:1766-71.
6. Lovas G, Szilagyi N, Majtenyi K, et al. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000;123:308-17.
7. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004;127:1009-18.
8. Ganter P, Prince C, Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 1999;25:459-67.
9. Bjartmar C, Kidd G, Mörk S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893-901.
10. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo, II: findings in multiple sclerosis. Neurology 1993;43:2632-7.
11. Lycklama à Nijeholt GJ, van Walderveen MAA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlations between MRI parameters, clinical subtypes and symptoms. Brain 1998;121:687-97.
12. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-8.
13. Filippi M, Campi A, Colombo B, et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol 1996;243:502-5.
14. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51:234-8.
15. Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and cervical cord pathology with primary progressive multiple sclerosis. Brain 2001;124:2540-9.
16. Lin X, Blumhardt LD, Constantinescu CS. The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. Acta Neurol Scand 2003;108:401-6.
17. 1 relaxation time mapping approach. J Neurol 2003;250:307-15.
18. Stevenson VL, Miller DH, Leary SM, et al. One year follow up of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:713-18.
19. Lin X, Tench CR, Turner B, et al. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon β-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry 2003;74:1090-4.
20. Brex PA, Leary SM, O'Riordan JI, et al. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:544-7.
21. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
22. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
24. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite score as a clinical trial outcome measure. Brain 1999;122:871-82.
25. Kameyama T, Hashizume Y, Ando T, et al. Morphometry of the normal cadaveric spinal cord. Spine 1994;19:2077-81.
26. Chard DT, Griffin CM, Rashid W, et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004;10:387-91.
27. Tiberio M, Chard DT, Altmann DR. Grey and white matter volume changes in early RRMS: a two-year longitudinal study. Neurology 2005;64(6):1001-7.
28. Plummer DL. Dispimage: a display and analysis tool for medical images. Riv Neuroradiol 1992;5:489-95.
29. Filippi M, Gawne-Cain ML, Gasperini C, et al. Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 1998;50:238-44.
30. Chard DT, Griffin CM, Parker GJ, et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:327-37.
31. Goldstein H. Multilevel statistical models. London: Arnold, 1995.
32. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001;58:961-7.
33. Ingle GT, Stevenson VL, Miller DH, et al. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003;125:2528-36.
34. Brass SD, Narayanan S, Antel JP, et al. Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci 2004;31:225-8.
35. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-8.
36. Lycklama à Nijeholt GJ, Bergers E, Kamphorst W, et al. Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis. A correlative study with conventional MRI, histopathology and clinical phenotype. Brain 2001;124:154-66.
37. Bot JC, Blezer EL, Kamphorst W, et al. The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. Radiology 2004;233:531-40.
38. Minagar A, Toledo EG, Alexander JS, et al. Pathogenesis of brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004;14:5S-10S.
39. Brex PA, O'Riordan JI, Miszkel KA, et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999;53:1184-90.
40. Lycklama à Nijeholt GJ, Uitdehaag BM, Bergers E, et al. Spinal cord magnetic resonance imaging in suspected multiple sclerosis. Eur Radiol 2000;10:368-76.
41. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1 a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-96.